CHEK1 and non-small cell lung carcinoma: In addition, Chk1 activation resulted in resistance to chemotherapeutic agents in non-small cell lung cancer cells, and its inhibition using AZD7762 abrogated such chemoresistance [27], suggesting that Chk1 activation may serve as an underlying resistance mechanism to chemotherapies and multiple targeted therapies.